Two switches, one molecule
An agonist is a substance that binds a receptor and turns it on. A dual agonist is a single molecule engineered to turn on two different receptors at the same time. In the GLP-1 world, the receptors in question are the GIP and GLP-1 receptors — the two incretin targets — and the landmark example is tirzepatide (Mounjaro, Zepbound). It’s sometimes nicknamed a “twincretin” because it copies both incretin hormones at once.
Why combine two targets
The rationale is straightforward: if activating the GLP-1 receptor helps with blood sugar and appetite, activating a second incretin receptor alongside it might do more. Tirzepatide’s GIP/GLP-1 approach is why it’s often discussed as a distinct generation from GLP-1-only medications like semaglutide. Exactly how much each receptor contributes is still an area of research, so it’s fair to call the two-target strategy promising and widely used rather than fully mapped out.
What to keep in mind
“Dual agonist” describes a mechanism, not a specific dose or brand — it tells you a drug hits two receptors, nothing more. It also sits on a spectrum: a standard GLP-1 receptor agonist hits one target, a dual agonist two, and a triple agonist three. The number just counts how many receptor “switches” the molecule flips. Which approach is right for a given person is a clinical decision — one to work through with your prescriber, alongside the GLP-1 overview.